DIRS.INFO The most relevant business & tech news

☆ Not all dividend strategies are the same. How to choose the best one for you
▼ + stars: | 2024-04-24 | by ( Michelle Fox | ) www.cnbc.com time to read: +6 min

She considers herself a dividend income investor, looking for names that provide a healthy payout for her clients. Her portfolio typically generates a 5% dividend yield or better. Honeywell has a 6% five-year annual dividend growth rate, he said. Lastly, CME Group not only has a 2.2% dividend yield, it tends to pay a special dividend once a year that's posted strong growth, he said. CME has five-year annual dividend growth of 15%, and a flawless balance sheet, he said.

Persons: Jenny Harrington, Kevin Simpson, Harrington, Simpson, Stocks, Kinder Morgan, Richard Kinder Organizations: Asset Management, Wealth, Merck, Verizon, SEC, Companies, Honeywell International, CME Group, Honeywell, Boeing, Group Locations: United States

☆ China health sector sees better sentiment from anti-graft drive - execs
▼ + stars: | 2023-11-09 | by ( Andrew Silver | ) www.reuters.com time to read: +2 min

SHANGHAI, Nov 9 (Reuters) - Business activities in China's healthcare sector are returning from a sudden near freeze that began in July when Beijing kicked off a year-long anti-corruption campaign, two foreign industry executives said. The campaign targets the bribing of doctors in drug and medical equipment sales and marks a sharp escalation of an anti-corruption drive in the sector that started years ago. The latest campaign has sent a chill through the sector, pummeling healthcare stocks and prompting some firms to cancel IPOs. The anti-graft drive initially caused huge business disruptions and many multinational pharmaceutical firms lost engagement with hospitals, executives said. China is one of the biggest healthcare markets for global healthcare companies but their business sentiment has turned fragile this year due to factors including the anti-graft drive.

Persons: We’ve, Larry Merizalde, Merizalde, Andrew Silver, Miyoung Kim, Robert Birsel Organizations: Beijing, Reuters, South, AstraZeneca, National Health Commission, Thomson Locations: SHANGHAI, China, Shanghai

☆ Barclays says this women's health pharma company could rally 48%
▼ + stars: | 2023-09-21 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Organon is an undervalued global play and leader in women's specialty health, according to Barclays. The company, with a portfolio of about 60 treatments and products focused on women's health, was spun off from Merck in 2021 . Barclays analyst Balaji Prasad initiated coverage on Organon with an overweight rating. The company could also generate more than $1 billion in annual free cash flow during that span, he added. Organon's prescription birth control Nexplanon is the key driver to its women's health portfolio as the Nexplanon "pipeline continues to progress toward commercialization," he added.

Persons: Balaji Prasad, Prasad, Nexplanon, — CNBC's Michael Bloom Organizations: Barclays, Merck, Health Locations: Wednesday's

☆ Reversing declining birth rates: No country has really got it right, says health-care company
▼ + stars: | 2023-08-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailReversing declining birth rates: No country has really got it right, says health-care companyKevin Ali of Organon discusses the costs of raising children and the complexity of the situation.

Persons: Kevin Ali, Organon

☆ The workplace can be rough for menopausal women. Employers are starting to step up
▼ + stars: | 2023-08-22 | by ( Jeanne Sahadi | ) edition.cnn.com time to read: +9 min

“The very topic of menopause has been taboo, particularly in the workplace, potentially further exacerbating the psychological burden of menopause symptoms,” the Mayo researchers noted. A 57-year old woman who has worked for years in the construction industry said she first experienced severe menopausal symptoms in her previous job. Menopausal symptoms might not be as troublesome at work if women could access more reliable information and care from their regular doctors. The plan lets any employee take up to 10 days off to address self-care issues of any kind, which the company notes can include dealing with menopausal symptoms. It was an attempt to find a way to help employees deal with their symptoms in ways they needed, Falcione told CNN.

Persons: “, ”, Mercer, it’s, White, “ I’ll, I’m, didn’t, Stephanie Faubion, you’re, ” Faubion, Faubion, Aaron Falcione, Falcione, Corina Leu, Leu Organizations: New, New York CNN, CNN, Mayo Clinic, Mayo, Mayo Clinic’s Center, Women’s Health, Merck, Mercer Locations: New York, United States, ”, Mayo

☆ Stocks making the biggest moves midday: Beyond Meat, Chegg, PNC Financial, Dish & more
▼ + stars: | 2023-08-08 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

The health care company reported earnings per share of $1.31. Organon posted $1.61 billion in revenue, beating analysts' expectations of $1.57 billion. Beyond Meat — The plant-based meat company fell 16% during midday trading after missing on second-quarter revenue, citing weak U.S. demand. The fragrance and cosmetics company reported revenue of $2.93 billion, falling shorter than analysts' estimates of $3.07 billion, according to StreetAccount. See Corp. — Shares of the packaging company lost 7% after See missed revenue expectations for the second quarter.

Persons: Moody's, Goldman Sachs, JPMorgan Chase, Organon, StreetAccount, Chegg, Charlie Ergen, EchoStar, Eli Lilly —, Eli Lilly, Palantir, —, Samantha Subin, Jesse Pound, Alex Harring, Hakyung Kim Organizations: PNC Financial, Citizens, T Bank —, T Bank, Webster, PNC, JPMorgan, Nordisk —, Technologies, Refinitiv . Fox Corp, Corp, —

☆ Final Trades: SLB, Organon, IQVIA & more
▼ + stars: | 2023-07-14 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: SLB, Organon, IQVIA & moreThe "Halftime Report" traders give their top picks to watch for the second half.

☆ Mark Cuban's online pharmacy set to launch Humira biosimilar
▼ + stars: | 2023-07-05 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

July 5 (Reuters) - Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's (CHRS.O) biosimilar version of AbbVie Inc's (ABBV.N) blockbuster rheumatoid arthritis drug Humira, Cuban said on Wednesday. Cost Plus Drugs will sell Yusimry for $569.27 plus dispensing and shipping fees. Coherus introduced its Humira biosimilar in the U.S. market this month alongside offerings from other drugmakers such as Boehringer Ingelheim, Sandoz and Organon (OGN.N). Cuban's Cost Plus Drugs aims to drive down the cost of drugs broadly by selling them at a 15% markup over its cost, plus pharmacy fees. Cuban said the company hopes to provide other biosimilar drugs as well.

Persons: Humira, Cuban, Coherus, AbbVie, Michael Erman, David Holmes Organizations: Cuban, Plus, Sandoz, Cuban's, Thomson Locations: U.S, Organon, Cuban

☆ Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
▼ + stars: | 2023-07-03 | by ( ) www.reuters.com time to read: +1 min

July 3 (Reuters) - Coherus BioSciences (CHRS.O) said on Monday it has launched a copycat version of AbbVie's (ABBV.N) Humira in the United States at a discount of more than 85% to the blockbuster arthritis drug. Coherus is the latest to launch a biosimilar to Humira in the U.S. market this month after Boehringer Ingelheim, Sandoz and Organon (OGN.N). Coherus said last month it would sell the biosimilar, branded as Yusimry, at $995 per carton, compared with the current list price of Humira of $6,922 per carton. The company has also partnered with billionaire entrepreneur Mark Cuban's pharmaceutical startup to sell the biosimilar at $569.27 plus dispensing and shipping fees. Usually prices fall, often dramatically, when multiple copycat versions of a widely-used medication enter the market.

Persons: Coherus, Boehringer Ingelheim, Mark, Sriparna Roy, Leroy Leo, Shounak Dasgupta, Arun Koyyur Organizations: Coherus BioSciences, Sandoz, Thomson Locations: United States, Humira, U.S, Organon, Bengaluru

☆ A son died, his parents tried to sue. How U.S. courts protect Big Pharma
▼ + stars: | 2023-06-26 | by ( ) www.reuters.com time to read: +26 min

His parents soon started exploring a lawsuit against Merck, the developer of the blockbuster asthma and allergy drug, Singulair, along with the manufacturer of the generic version their son took. That meant Merck had written the warning label, with federal approval, on the generic version of Singulair that Nicholas England took. But his parents couldn’t sue Merck, either, because their son had never taken its name-brand version of Singulair. The generic drug manufacturer that made the pills England took, Teva Pharmaceuticals, did not respond to inquiries. Since Merck’s patent on Singulair expired in 2012, major generic drug manufacturers have sold millions of prescriptions under the drug’s scientific name, montelukast.

Persons: Nicholas England, Nicholas, Merck, ”, Jennifer England, Nicholas’s, ” Merck, Organon, “, George W, Bush, Daniel Troy, Troy, Medtronic, Nicholas England’s, Adam Zimmerman, ” Zimmerman, Jay Lefkowitz, Ellis, shouldn’t, Bayer, drugmaker Wyeth, Phenegran, Jan Gilpin’s, mumbling, ” Gilpin, ” “, hadn’t, Singulair, Gilpin, Stephane Bissonnette, suicidality, Dr, Judith Kramer, Duke, Robert England, Robert said, Kim Beck Organizations: Merck, U.S, Teva Pharmaceuticals, Reuters, U.S . Food, Drug Administration, FDA, Big, Corporate America, Corporations, Administration, ”, New, University of Southern California’s Gould School of Law, Norfolk, Union Pacific, Federal Railroad Safety, Pacific, GlaxoSmithKline, Monsanto, Bayer, Parent Locations: Virginia, England, U.S, New York, Kirkland, East Palestine , Ohio, Louisiana, Atlanta, Vermont, Wise , Virginia, Wisconsin

☆ Morning Bid: Growth trumps rates
▼ + stars: | 2023-02-16 | by ( ) www.reuters.com time to read: +6 min

While there were some questions about seasonal adjustments in the data, economists were impressed that sales growth was pretty broad based and have scrambled to re-crunch first quarter U.S. output forecasts as a result. There may be a more mixed picture from Thursday's data slate on producer prices, housing starts and weekly jobless claims. Even though rates futures and Treasury yields ticked back a bit today, pricing now has Fed policy rates moving as high as 5.25% and staying above 5% all year. And while full-year earnings growth estimates for S&P500 companies have sunk to zero, consensus forecasts are now pencilling in a rebound of almost 12% next year. Uncertainty about the pace of growth and annual tax receipts in April makes it difficult for government officials to predict the exact "X-date", it said.

☆ EMA's safety committee starts review of cold medicines
▼ + stars: | 2023-02-10 | by ( ) www.reuters.com time to read: 1 min

Feb 10 (Reuters) - A European Medicines Agency (EMA) committee said on Friday it has started a review of decongestant medicines for cold and flu that contain the ingredient pseudoephedrine following safety concerns. The EMA said the review was due to reports of conditions affecting blood vessels in the brain in some patients who took pseudoephedrine-containing medicines. Pseudoephedrine is a drug that is used alone or in combination with other medicines to treat a blocked nose due to cold, flu or allergy. Makers of pseudoephedrine-containing drugs include Reckitt Benckiser (RKT.L), McNeil Products Ltd and Organon & Co (OGN.N). Reporting by Sriparna Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

With a majority of S & P 500 companies having posted their quarterly results, investors' focus will turn toward inflation and the consumer price index reading in the upcoming week. The three major indexes are on pace to end the week down, with the S & P 500 poised to post its worst performance since December. Sharp declines for Alphabet , which is off by more than 9% this week, dragged the tech-heavy index. January's consumer price index With the latest Powell speech in the books, investors are now looking ahead to the consumer price index for insight into the pace of inflation. "Retail sales and CPI is really driven by the consumer, and a lot of eyes are on how the consumer doing," Bruno said.

☆ Cramer's lightning round: I like Nucor over Cleveland-Cliffs
▼ + stars: | 2023-01-25 | by ( Krystal Hur | ) www.cnbc.com time to read: 1 min

Loading chart...Organon & Co : "I do not understand why this stock sells at five times earnings." Loading chart...Alibaba Group Holding Ltd : "It's the only China stock I'd buy." Loading chart...Cleveland-Cliffs Inc : "Why be in Cleveland-Cliffs when you can be in Nucor ?" Loading chart...Barrick Gold Corp : "I think the stock is breaking out here. Disclaimer: Cramer's Charitable Trust owns shares of Honeywell.

☆ Goldman Sachs' inflation picks — 10 stocks to buy if prices are peaking
▼ + stars: | 2022-12-13 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Here are 10 of those names: Two pharma biotech companies made the cut, including Viatris , which has the highest earnings yield on the list. In the banking space, KeyCorp is among the names that should fare well, according to Goldman Sachs. Also on the list is Microchip Technology , which has an 8% earnings yield and 4% estimated earnings growth in 2023. Lastly, Molson Coors Beverage should also outperform amid decelerating inflation, according to Goldman. Molson Coors has an 8% yield and it's estimated earning growth for 2023 is 6%, per Goldman.

☆ Goldman’s official 2023 outlook is here: Where it thinks the market is headed and what to buy
▼ + stars: | 2022-11-22 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Goldman Sachs is predicting zero earnings growth in 2023, with stocks ending the next year essentially flat. The firm is pegging 2023 S & P 500 earnings-per-share flat at $224 and the index ending next year at 4,000, just over 1% from Monday's close. The bank's EPS yield for the next 12 months is 14%, while its estimated EPS will decline by 12% in 2023, according to Goldman. Walgreens's EPS yield for the next 12 months is 11% and its estimated 2023 earnings growth is 2%, Goldman found. Its next-12-month EPS yield is 7% and its estimated EPS growth for 2023 is 4%, according to Goldman.

☆ It's 'early innings' in the fertility market. Here's how to play the booming business with under-the-radar names
▼ + stars: | 2022-11-17 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

The multibillion dollar global fertility market is ripe with opportunity. For investors thinking about the fertility market, pharma firms may come to mind. In fact, the number of employers looking at fertility benefits as a "must have" has skyrocketed, she said. The global market size for fertility within the private women's health market should reach $72 billion by 2027, a report by FemTech Focus and Coyote Ventures found. Just like there were a wave of fintech companies going public, she expects fertility companies to eventually follow suit.

☆ The fund manager who's in the green this year by not playing 'the relative game'
▼ + stars: | 2022-11-14 | by ( Alex Harring | ) www.cnbc.com time to read: +7 min

J. Dale Harvey, founder and chief investment officer at Poplar Forest, manages a fund that's beating the S & P 500 this year. Harvey has led the Poplar Forest Partners Fund (PFPFX) since it was established on Dec. 31, 2009 with a "contrarian" mindset. "People can get sucked into the sort of the relative game, which which we don't play," he said. The fund took a dip with the rest of the market in September before marching back up in the following weeks. He noted value stocks, where he mainly looks, were "in the doghouse" for much of the 2010s as technology and other growth stocks drove the market.

☆ JPMorgan downgrades Teva as generic medication business struggles
▼ + stars: | 2022-11-14 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Teva Pharmaceutical is hard to like as it continues to be weighed down by underperformance in some business areas, JPMorgan says. The new price target implies upside of just 5.5% from Friday's close. Schott noted the company has been able to continue paying down debt as a positive, but said it would need to continue allocating cash pay towards this. The stock's performance could be impacted by improvements in generics, a favorable opioid settlement or if the company is able to stave off competition on its migraine medication Ajovy. Teva shed 2.3% in the premarket and is up 18.4% compared with the start of the year.

☆ Jim Cramer gives his take on Organon
▼ + stars: | 2022-10-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJim Cramer gives his take on OrganonCramer on Tuesday explained his thoughts on pharmaceutical firm Organon.

☆ Cramer's lightning round: Wait for Texas Roadhouse to come down
▼ + stars: | 2022-10-17 | by ( Krystal Hur | ) www.cnbc.com time to read: 1 min

I like profitable companies with good balance sheets. Loading chart...Veru Inc : "A lot of people bet against it, so it could be a very binary, up big, down big situation." Loading chart...Texas Roadhouse Inc : "We have to wait for that one to come down, because it's had too big a move." Loading chart...Organon & Co : "We are going to find out what this story is, and then we're going to come back to you." Dice Therapeutics Inc : "I can not recommend it, particularly because the company is losing money hand over fist."

☆ Goldman finds cheap stocks with strong and growing dividend yields for this market turmoil
▼ + stars: | 2022-09-28 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

In the previous session, the S & P 500 reached a new bear market low of 3,623.29, indicating that stocks could still have further to fall. Investors wanting to counter the market turbulence with income can look to stocks with high dividend yield and growth. Goldman Sachs has a basket of cheap stocks, with a median dividend yield of 3.4%, compared to the S & P 500's 1.8%. That's followed closely by Ford Motor, which has a 3.4% dividend yield, and projected growth of 100%. Among financials, Morgan Stanley has the fastest projected dividend growth at 21%.

☆ Finding yield in health care stocks during the market storm
▼ + stars: | 2022-09-23 | by ( Bertha Coombs | ) www.cnbc.com time to read: +3 min

Investors have looked to health care as a port in the storm during the stock market's volatility over the last year. In health care, "you still have companies that are throwing off good yield, so you get stability and good dividend yields." Biotech and pharmaceuticals industries have an average dividend yield of 2.6%, ranking just behind the consumer staples, utilities, and energy sectors. Just two stocks made the grade: drug maker AbbVie and pharmacy and health services giant CVS Health. The company, which includes pharmacy benefits as well the Aetna health insurance division, has a dividend yield of 2.1%.

Search resuls for: "Organon"

23 mentions found